A
Alessandro Pancrazzi
Researcher at University of Florence
Publications - 67
Citations - 5198
Alessandro Pancrazzi is an academic researcher from University of Florence. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 32, co-authored 64 publications receiving 4651 citations.
Papers
More filters
Journal ArticleDOI
Mutations and prognosis in primary myelofibrosis
Alessandro M. Vannucchi,Tl Lasho,Paola Guglielmelli,Flavia Biamonte,Animesh Pardanani,Arturo Pereira,Christy Finke,Joannah Score,Naseema Gangat,Carmela Mannarelli,Rp Ketterling,Giada Rotunno,Ra Knudson,Mc Susini,Rr Laborde,Ambra Spolverini,Alessandro Pancrazzi,Lisa Pieri,Rossella Manfredini,Enrico Tagliafico,Roberta Zini,Amy V. Jones,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Daniela Pietra,Elisa Rumi,Francisco Cervantes,G Barosi,Mario Cazzola,Nc Cross,Ayalew Tefferi +31 more
TL;DR: Mutational profiling for ASXL1, EZH2, SRSF2 and IDH identifies PMF patients who are at risk for premature death or leukemic transformation.
Journal ArticleDOI
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno,Carmela Mannarelli,Paola Guglielmelli,Annalisa Pacilli,Alessandro Pancrazzi,Lisa Pieri,Tiziana Fanelli,Alberto Bosi,Alessandro M. Vannucchi +8 more
TL;DR: Genotyping for CALR mutations represents a novel useful tool for establishing a clonal myeloproliferative disorder in JAK2 and MPL wt patients with thrombocytosis and may have prognostic and therapeutic relevance.
Journal ArticleDOI
Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden
Alessandro M. Vannucchi,Elisabetta Antonioli,Paola Guglielmelli,Giovanni Longo,Alessandro Pancrazzi,Vanessa Ponziani,Costanza Bogani,Pierluigi Rossi Ferrini,Alessandro Rambaldi,Vittoria Guerini,Alberto Bosi,Tiziano Barbui +11 more
TL;DR: It is concluded that a burden of JAK2V617F allele greater than 75% at diagnosis points to PV patients with high-risk disease.
Journal ArticleDOI
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Paola Guglielmelli,Terra L. Lasho,Giada Rotunno,Joannah Score,Carmela Mannarelli,Alessandro Pancrazzi,Flavia Biamonte,Animesh Pardanani,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Tiziana Fanelli,Daniela Pietra,Elisa Rumi,Christy Finke,Naseema Gangat,Rhett P. Ketterling,Ryan A. Knudson,C A Hanson,Alberto Bosi,Arturo Pereira,Rossella Manfredini,Francisco Cervantes,Giovanni Barosi,Marie Cazzola,Nicholas C.P. Cross,Alessandro M. Vannucchi,Ayalew Tefferi +27 more
TL;DR: It is concluded that the ‘number’ of prognostically detrimental mutations provides added value in the combined molecular and clinical progNostication of PMF.
Journal ArticleDOI
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
Elisabetta Antonioli,Paola Guglielmelli,Alessandro Pancrazzi,Costanza Bogani,Maria Verrucci,Vanessa Ponziani,Giovanni Longo,Alberto Bosi,Alessandro M. Vannucchi +8 more
TL;DR: The data indicate that immunophenotypic modulation in ALL patients undergoing treatment can (at least in part) be explained by the induction of cell death, resulting in loss of membrane antigens and higher aspecific staining.